-
Mashup Score: 25Redefining Rare Genitourinary Cancers: An Initiative Led by the Global Society of Rare Genitourinary Tumors - 2 month(s) ago
Rare cancers account for 20–25% of all cancers diagnosed annually but there is no consensus on the definition of a rare cancer and substantial geographic heterogeneity. The Global Society of Rare Genitourinary Tumors is dedicated to education and research for rare genitourinary tumors.
Source: www.europeanurology.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 69The Efficacy and Safety of Metastasis-directed Therapy in Patients with Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies - 2 month(s) ago
Metastasis-directed therapy results in promising clinical outcomes and low rates of adverse events. It can be a valuable treatment option either for oligorecurrent patients wishing to avoid androgen deprivation therapy or as a treatment intensification method. Phase 3 trials are necessary.
Source: www.europeanurology.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 4Primary Whole-gland Ablation for the Treatment of Clinically Localized Prostate Cancer: A Focal Therapy Society Best Practice Statement - 2 month(s) ago
Localized prostate cancer can be treated effectively with minimally invasive whole-gland ablation with comparable intermediate- to long-term oncological control with excellent pad-free continence rate at 1 yr. Treatment decisions consistent with patient values and preferences should be encouraged.
Source: www.europeanurology.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 11Management of Lymph Node–positive Penile Cancer: A Systematic Review - 2 month(s) ago
Surgery remains the standard for lymph-node (LN) metastatic penile cancer. Surveillance or delayed LN dissection (LND) risks missing a curative opportunity. Minimally invasive techniques seem to be feasible and may reduce wound related complications. (Neo)adjuvant treatment has no proven benefit in pN1 disease. More advanced disease is rarely cured by surgery alone and multimodal treatment should be considered after multidisciplinary team discussion. Further prospective and randomised trials on minimally invasive LND, multimodal/novel systemic therapies, and management of recurrent LN are needed.
Source: www.europeanurology.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 7
Treatment with lenvatinib plus pembrolizumab had a manageable safety profile and did not show superior antitumor efficacy to treatment with pembrolizumab plus placebo. First-line pembrolizumab monotherapy remains a standard of care for certain patients who are ineligible for cisplatin-based or any platinum-based chemotherapy.
Source: www.europeanurology.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 69The Efficacy and Safety of Metastasis-directed Therapy in Patients with Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies - 2 month(s) ago
Metastasis-directed therapy results in promising clinical outcomes and low rates of adverse events. It can be a valuable treatment option either for oligorecurrent patients wishing to avoid androgen deprivation therapy or as a treatment intensification method. Phase 3 trials are necessary.
Source: www.europeanurology.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 16January 2024 Reviewer of the Month - Shilpa Gupta: European Urology - 2 month(s) ago
January 2024 Dr. Shilpa Gupta is the Director of the Genitourinary Medical Oncology at Taussig Cancer Institute at the Cleveland Clinic and Clinical Professor of Medicine at the Lerner College of Medicine. She is a clinical and translational scientist with interests in novel drug development and biomarker discovery. She is the Co-Chair of the Hoosier Cancer Research Network (HCRN) GU Working Group and serves on the scientific advisory and steering committee for Bladder cancer Advocacy Network (BCAN),
Source: www.europeanurology.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 15A 23-Gene Prognostic Index Predicts Progression and Bacillus Calmette-Guérin Response in Non–muscle-invasive Bladder Cancer - 3 month(s) ago
Prediction of the clinical behavior of non–muscle-invasive bladder cancer (NMIBC) and responses to bacillus Calmette-Guérin (BCG) therapy remains a formidable challenge [1] despite valuable insights facilitated by recent high-throughput technologies [2–4]. To enhance NMIBC prognostication, we used deep learning for an analysis of long-term follow-up data (median 89.5 mo in the discovery cohort) to develop a prognostic index (PI) for NMIBC progression (Supplementary Figs. 1 and 2). Disease progression was defined as an increase in stage after relapse from either Ta or T1 to stage ≥T2.
Source: www.europeanurology.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 32Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes - 3 month(s) ago
We observed different complete response rates and an independent association with survival in bladder cancer molecular subtypes for patients treated with neoadjuvant chemotherapy and radical cystectomy.
Source: www.europeanurology.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 2Safety Analyses of the Phase 3 VISION Trial of [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer - 3 month(s) ago
We show that longer exposure to 177Lu-PSMA-617 treatment for up to six cycles was not associated with greater toxicity risk. Safety analyses support a favourable benefit-risk profile for six cycles of 177Lu-PSMA-617 in patients with progressive, prostate-specific membrane antigen–positive, metastatic castration-resistant prostate cancer.
Source: www.europeanurology.comCategories: General Medicine News, UrologyTweet
Articles in Press: Redefining Rare Genitourinary Cancers: An Initiative Led by the Global Society of Rare Genitourinary Tumors @AndreaNecchi @SpiessPhilippe https://t.co/LBjfrvg7G1 #UroSoMe #Medtwitter #articlesinpress #genitourinarycancer https://t.co/dLcC56EbqO